Chemosensory Dysfunction and Recovery in Endoscopic Endonasal Skull Base Surgery

Sponsor
Johns Hopkins University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05912881
Collaborator
North American Skull Base Society (Other)
50
1
2
35
1.4

Study Details

Study Description

Brief Summary

The investigators hypothesize that patients undergoing endoscopic endonasal skull base surgery experience clinically meaningful and modifiable disruptions in postoperative chemosensory function and quality of life, and the investigators further hypothesize that olfactory training in the postoperative period may significantly hasten normalization of patients' chemosensory perturbations. This tailored prospective study seeks to fulfill a significant gap in the understanding of the characteristics, implications, and treatment options for postoperative olfactory and gustatory impairment following endoscopic endonasal skull base surgery.

Condition or Disease Intervention/Treatment Phase
  • Other: Olfactory training
  • Other: Placebo training
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants are enrolled into treatment or placebo groups for the entirety of the study.Participants are enrolled into treatment or placebo groups for the entirety of the study.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
All study team members and study participants are blinded as to which olfactory training kit (treatment vs placebo) the participants received.
Primary Purpose:
Treatment
Official Title:
Chemosensory Dysfunction and Recovery in Endoscopic Endonasal Skull Base Surgery
Actual Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2026
Anticipated Study Completion Date :
Jan 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo

Participants receive placebo olfactory training kits that only contain medium chain triglycerides that lack any discernible odor

Other: Placebo training
Participants perform olfactory training using sticks filled with unscented medium chain triglycerides.

Experimental: Treatment

Participants receive treatment olfactory training kits that contain essential oils that have scents (lavender, lemon, clove, eucalyptus)

Other: Olfactory training
Participants perform olfactory training using sticks filled with scented essential oils.

Outcome Measures

Primary Outcome Measures

  1. Change in Olfactory function as assessed by the Sniffin Sticks olfactory testing kit [Pre-operative visit (baseline), 2 weeks post-operative, 1 month post-operative, 3 months post-operative]

    Olfactory function as determined using the commercially available "Sniffin' Sticks" olfactory testing kit. Olfactory function is tested in three domains: threshold, discrimination, and identification. For threshold testing, the most dilute concentration of odorant that the participant is able to reliably detect is determined. In discrimination testing, the participant is evaluated on their ability to discern the unique scent among three scented sticks. In identification testing, the patient names the smells using a multiple choice form which offers four definitions for every Sniffin' stick, only one of which is correct.

Secondary Outcome Measures

  1. Change in Quality of Life as assessed by the Anterior Skull Base Nasal Inventory-12 [Pre-operative visit (baseline), 2 weeks post-operative, 1 month post-operative, 3 months post-operative, 6 months post-operative]

    Quality of life questionnaire. Score range 0-60, where higher score is worse and indicates more onerous symptoms.

  2. Change in Quality of Life as assessed by the ODOR (Olfactory Dysfunction Outcomes Rating) questionnaire [Pre-operative visit (baseline), 2 weeks post-operative, 1 month post-operative, 3 months post-operative, 6 months post-operative]

    Quality of life questionnaire. Score range 0-112, where higher score is worse and indicates greater degree of olfactory dysfunction.

  3. Change in Quality of Life as assessed by the Skull Base Inventory [Pre-operative visit (baseline), 2 weeks post-operative, 1 month post-operative, 3 months post-operative, 6 months post-operative]

    Quality of life questionnaire. Score range 0-100, where higher score is better, indicative of less burden on quality of life.

  4. Change in Quality of smell and taste as assessed by a Visual analog scale [Pre-operative visit (baseline), 2 weeks post-operative, 1 month post-operative, 3 months post-operative, 6 months post-operative]

    Quality of smell and taste as indicated on a visual analog scale. Score range 0-100, where higher score is better and indicative of better smell and taste function.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • English Speaking

  • preoperative diagnosis of benign sellar or parasellar skull base pathology

Exclusion Criteria:
  • preoperative diagnosis of malignant sellar or parasellar skull base pathology

  • history of endoscopic sinus surgery

  • history of skull base surgery

  • history of radiation therapy or other local treatments for the management of facial, sinonasal, or cranial pathologies

  • history of chronic rhinosinusitis

  • history of neurocognitive disorder

  • history of intrinsic chemosensory pathology

  • history of cardiac pacemaker

  • history of gastrectomy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Johns Hopkins Medicine Baltimore Maryland United States 21224

Sponsors and Collaborators

  • Johns Hopkins University
  • North American Skull Base Society

Investigators

  • Principal Investigator: Nicholas Rowan, MD, Johns Hopkins School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT05912881
Other Study ID Numbers:
  • IRB00311777
First Posted:
Jun 22, 2023
Last Update Posted:
Jun 22, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 22, 2023